Intervet International, B.V. et al. vs Boehringer Ingelheim Vetmedica, Inc. et al.

Termination Decision Document

Joint Request to File Settlement Agreement (Exhibit 1080) as Business Confidential Information Pursuant to 35 U.S.C. Sec. 317(B) and 37 C.F.R. Sec. 42.74(C)

Joint Motion to Terminate Pursuant to 35 USC Sec. 317 and 37 CFR Sec. 42.74

Confidential Settlement Agreement

Trial Instituted Document

Scheduling Order

Exhibit 2406 (part 6a) - Prosecution History of U.S. Patent Application No. 13/106,606

Exhibit 2401 - Allan

Exhibit 2403 - The Pig Site

Exhibit 2404 - Ramshaw

Exhibit 2409 - April 16, 2019 Decision Denying Institution in IPR2018-01789 (Paper 9)

Exhibit 2410 - Jestin et al., U.S. Patent No. 7,223,407

Exhibit 2411 - Audonnet et al., U.S. Patent No. 6,943,152

Exhibit 2413 - Siebel

Exhibit 2415 - Chevez

Patent Owner's Preliminary Response

Exhibit 2402 - Ellis

Exhibit 2408 - April 16, 2019 Decision Denying Institution in IPR2018-01788 (Paper 9)

Exhibit 2412 - Fenaux 2003

Exhibit 2414 - Desrosiers

Exhibit 2418 - U.S. Patent Appl. No. 11/617,435

Exhibit 2416 - IPR2018-00919 Preliminary Response

Exhibit 2417 - Bowersock

Exhibit 2405 (part 5) - Prosecution History of U.S. Patent Application No. 14/661,969

Exhibit 2406 (part 1) - Prosecution History of U.S. Patent Application No. 13/106,606

Exhibit 2406 (part 4) - Prosecution History of U.S. Patent Application No. 13/106,606

Exhibit 2406 (part 10) - Prosecution History of U.S. Patent Application No. 13/106,606

Exhibit 2407 (part 2) - Prosecution History of U.S. Patent Application No. 12/136,923

Exhibit 2407 (part 4) - Prosecution History of U.S. Patent Application No. 12/136,923

Exhibit 2407 (part 5) - Prosecution History of U.S. Patent Application No. 12/136,923

Exhibit 2407 (part 7) - Prosecution History of U.S. Patent Application No. 12/136,923

Exhibit 2405 (part 1) - Prosecution History of U.S. Patent Application No. 14/661,969

Exhibit 2405 (part 2) - Prosecution History of U.S. Patent Application No. 14/661,969

Exhibit 2405 (part 3) - Prosecution History of U.S. Patent Application No. 14/661,969

Exhibit 2405 (part 4) - Prosecution History of U.S. Patent Application No. 14/661,969

Exhibit 2406 (part 2) - Prosecution History of U.S. Patent Application No. 13/106,606

Exhibit 2406 (part 3) - Prosecution History of U.S. Patent Application No. 13/106,606

Exhibit 2406 (part 5) - Prosecution History of U.S. Patent Application No. 13/106,606

Exhibit 2406 (part 7) - Prosecution History of U.S. Patent Application No. 13/106,606

Exhibit 2406 (part 9) - Prosecution History of U.S. Patent Application No. 13/106,606

Exhibit 2407 (part 1) - Prosecution History of U.S. Patent Application No. 12/136,923

Exhibit 2407 (part 3) - Prosecution History of U.S. Patent Application No. 12/136,923

Exhibit 2407 (part 6) - Prosecution History of U.S. Patent Application No. 12/136,923

Exhibit 2406 (part 8) - Prosecution History of U.S. Patent Application No. 13/106,606

Exhibit 2406 (part 6b) - Prosecution History of U.S. Patent Application No. 13/106,606

Petitioner's Updated Mandatory Notices

Petitioner's Updated Power of Attorney

Notice of Accord Filing Date

Patent Owner's Mandatory Notices Pursuant to 37 C.F.R. 42.8(a)(2)

Patent Owner's Power of Attorney

Complaint in Boehringer Ingelheim Vetmedica, Inc. v. Merck & Co., Inc. and Intervet Inc. a/k/a Merck Animal Health, Case No. 2:18-cv-09534-JMV-JBC (D.N.J. May 21, 2018) (ECF No. 1)

Petitioner's Power of Attorney

Roof et al., U.S. Patent No. 9,669,087 ("the '087 Patent")

Jestin et al., U.S. Patent No. 6,703,023 ("Jestin")

Blanchard et al., Protection of swine against post-weaning multisystemic wasting syndrome (PMWS) by porcine circovirus type 2 (PCV-2) proteins, Vaccine 21:4565-4575 (2003) ("Blanchard")

Merial, Inc.'s Petition for Inter Partes Review of U.S. Patent No. 8,008,001 Under 35 U.S.C. §§ 311-319 and 37 C.F.R. § 42.1-.80 & 42.100-.123

Declaration of Merrill L. Schaeffer, Ph.D. and enclosures

Patrick Halbur & Tanja Opriessnig, Update on Porcine Circovirus Type 2 (PCV2)-Associated Diseases, Vet. Diagn. Production Animal Med. ("Halbur")

Fenaux et al., Genetic Characterization of Type 2 Porcine Circovirus (PCV-2), etc., Journal of Clinical Microbiology, 38:2494-2503 (2000) ("Fenaux 2000")

Meng et al., International Publication No. WO 2003/049703 ("Meng")

M. Fenaux, et al., A Chimeric Porcine Circovirus (PCV) with the Immunogenic Capsid Gene of the Pathogenic PCV Type 2 (PCV2), et al., 78 J.Virol. 6297 (2004) ("Fenaux")

Bublot et al., U.S. Patent No. 6,497,883 ("Bublot")

Prosecution History of U.S. Patent No. 9,669,087 (Part 1)

Prosecution History of U.S. Patent No. 9,669,087 (Part 2)

Declaration of Christopher C. L. Chase

Porntippa Nawagitgul, Igor Morozov, Steven R. Bolin, Perry A. Harms, Steven D. Sorden & Prem S. Paul, Open reading frame 2 of porcine circovirus type 2 encodes a major capsid protein, 81 J.Gen.Virol. 2281 (2000) ("Nawagitgul")

H. Jorio, R. Tran & A. Kamen, Stability of Serum-Free and Purified Baculovirus Stocks Under Various Storage Conditions, Biotechnol Prog. 22, 319-325 (2006) ("Jorio")

G. Sala, et al., Development of Monocolonal Antibodies Based on ELISAs, etc., The 5th International Congress of Veterinary Virology, Veterinary Virology in the New Millennium (2000) ("Sala")

Parisot et al., International Publication No. WO 2005/009462 A2 (Feb. 3, 2005) ("Parisot")

G. Reynaud, S. Beseme, A. Brun, C. Charreyre, S. Desgouilles, P. Jeannin & S. Rehbein, Safety of a High Dose Administration of an Inactivated Adjuvanted PCV2 Vaccine in Conventional Gilts, 1 PROCEEDINGS OF THE 18TH IPVS CONGRESS 87 (2004) ("Reynaud")

D. Mahe, et al., Differential recognition of ORF2 protein from type 1 and type 2 porcine circoviruses and identification of immunorelevant epitopes, 81 J. Virol. 1815 (2000) ("Mahe")

M. Fort, A. Olvera, M. Sibila, J. Segales & E. Mateu, Direction of Neutralizing Antibodies in Postweaning Multisystemic Wasting Syndrome (PMWS)-Affected and Non-PMWS-Affected Pigs, Veterinary Microbiology 125, 244-255 (2007) ("Fort")

Y. Okuda, et al., Experimental Reproduction of Postweaning Multisystem Wasting Syndrome in Cesaren-deprived, etc., 15 J. Vet. Diag. Invest 107-114 (2003) ("Shibata")

L. Truchan, R. Jolie, P. Runnels & D. McGavin, Eighteen Week Duration of Immunity in Pigs Vaccinated at 3 or 8 Weeks of Age with One Dose of a Mycoplasma hyopneumoniae Bacterin, American Association of Swine Practitioners (2000) ("Truchan")

A. Dawson, R. E. Harvey, S. J. Thevasagayam, J. Sherington, A. R. Peters, Studies of the Field Efficacy and Safety of a Single-Dose Mycoplasma hyopneumoniae Vaccine for Pigs, The Veterinary Record (Nov. 2, 2002) ("Dawson")

Haemophilus Parasuis Bacterin Ingelvac HP-1 Product Label, Boehringer Ingelheim Vetmedica, Inc.

Monique M. van Oers, Vaccines for Viral and Parasitic Diseases Produced with Baculovirus Vectors, 68 Advances Virus Res. 193 (2006) ("van Oers")

M. Roof, K. Burkhart, and F. Zuckermann, Evaluation of the Immune Response and Efficacy of 1 and 2 dose commercial Mycoplasma hyopneumoniae bacterins, American Association of Swine Veterinarians (2000) ("Roof")

Product News, National Hog Farmer (Dec. 15, 2003).

M. Kiupel, G.W. Stevenson, S.K. Mittal, E.G. Clark & D.M. Haines, Circovirus-like Viral Associated Disease in Weaned Pigs in Indiana, 35 Vet. Pathol. 303 (1998) ("Kiupel")

John C.S. Harding, The clinical expression and emergence of porcine circovirus 2, 98 Vet. Microbiol. 131 (2004) ("Harding 2004")

F. McNeilly, I. McNair, D. P. Mackie, B. M. Meehan, S. Kennedy1 D. Moffett, J. Ellis, S. Krakowka & G. M. Allan, Production, characterisation and applications of monoclonal antibodies to porcine circovirus 2, 146 Arch Virol 909 (2001) ("McNeilly")

Gordon M. Allan & John A. Ellis, Porcine circoviruses: a review, 12 J. Vet. Diagn. Invest. 3 (2000) ("Allan 2000")

Inger Marit Brunborg, et al., Quantitation of porcine circovirus type 2 isolated from serum/plasma and tissue samples, etc., 122 J. Virological Methods 171 (2004) ("Brunborg")

J. Carr & Garth Veterinary Group, Garth Pig Stockmanship Standards, The Pig Site (Sept. 14, 2018, 2:45 p.m.) http://www.thepigsite.com/stockstds/17/growth-rate/. ("Carr").

Chanhee Chae, Commercial porcine circovirus type 2 vaccines: Efficacy and clinical application, 194 Vet. J. 151 (2012) ("Chae").

New Mycoplasma Vaccine Offers Convenience, Effective Protection, High Plains/Midwest Ag Journal (Feb. 14, 2005) http://www.hpj.com/archives/new-mycoplasma-vaccine-offers-convenience-effective-protection/article_aab328d5-1df1-590e-aed8-bc11330a46eb.html.

Erysipelothrix Rhusiopathiae-Haemophilus Parasuis Vaccine and Methods of Using the Same, International Publication No. WO 2005/041890 A2.

John C.S. Harding & Edward G. Clark, Recognizing and diagnosing postweaning multisystemic wasting syndrome (PMWS), 5 Swine Health and Production 201 (1997) ("Harding 1997")

G. M. Allan, et al., Isolation of porcine circovirus-like viruses from pigs with a wasting disease in the USA and Europe, 10 J. Vet. Diagn Invest 3 (1998) ("Allan 1998")

Yuna Kim, Jinhyun Kim, Kyoungsoo Kang & Young S. Lyoo, Characterization of the Recombinant Proteins of Porcine Circovirus Type2 Field Isolate Expressed in the Baculovirus System, 3 J. Vet. Sci. 19 (2002) ("Kim")

Joaquim Segales, Gordon M. Allan & Mariano Domingo, Porcine circovirus diseases, 6 Animal Health Res. Rev. 119 (2005) ("Segales")

Annette Mankertz & Bernd Hillenbrand, Replication of porcine circovirus type 1 requires two proteins encoded by the viral rep gene, 279 Virology 429 (2001) ("Mankertz 2001")

Roman M. Pogranichniy, Kyoung-Jin Yoon, Perry A. Harms, Sabrina L. Swenson, Jeffrey J. Zimmerman & Steven D. Sorden, Characterization of immune response of young pigs to porcine circovirus type 2 infection, 13 Viral Immunol. 143 (2000) ("Pogranichnyy")

A. Mankertz., J. Mankertz, K. Wolf & H.J. Buhk, Identification of a protein essential for replication of porcine circovirus, 79 J.Gen.Virol. 381 (1998) ("Mankertz 1998")

P. Rueda, J. Fominaya, J. Langeveld, C. Bruschke, C. Vela & J. Casal, Effect of Different Baculovirus Inactivation Procedures on the Integrity and Immunogenicity of Porcine Parvovirus-like Particles, 19 Vaccine 726-734 (2001) ("Rueda")

Ellis et al., U.S. Patent No. 6,517,843 ("Ellis")

P.C. Liao, Y.L. Lin, M.H. Jong & W.B. Chung, Efficacy of Foot-and-Mouth Disease Vaccine in Pigs with Single Dose Immunization, 21 Vaccine 1807-1810 (2003) ("Liao")

M. Kuhn, Comparative Safety Evaluation of a One-dose M.hyopneumoniae bacterin ("RespiSure-One") and a Competitor One-dose M. hyopneumoniae bacterin, Pfizer Animal Health Swine Veterinary Services ("Respisure One")

B. Bosworth, Evaluation of a One-dose Mycoplasma hyopneumoniae Bacterin and a One-dose Erysipelas Rhusiopathie Bacterin, American Association of Swine Veterinarians (2004) ("Pneumonostar Myco _ Panstar Ery")

M. Hammer, B. Bosworth, D. Stine, E. Springer, T. Johnson, Evaluation of One-Dose MycoPlasma hyopneumoniae bacterin (PneumoSTAR Myco) at 23 Weeks Post Vaccination, American Association of Swine Veterinarians (2005)

European Patent No. EP2281829

S.J. Barteling & J. Vreeswijk, Developments in Foot-and-Mouth Disease Vaccines, 9 Vaccine 75-86 (Feb. 1991) ("Barteling")

H. Bahnemann, Inactivation of Viral Antigens for Vaccine Preparation with Particular Reference to the Application of Binary Ethylenimine, 8 Vaccine 299-303 (1990) ("Bahnemann")

Declaration of Dr. Phil Hayes ("Hayes Declaration")

M.M. Hulst, D.F. Westra, G. Wensvoort & R.J.M. Moormann, Glycoprotein E1 of Hog Cholera Virus Expressed in Insect Cells Protects Swine from Hog Cholera, 67 J. Virology 9:5435-5442 (Sept. 1993) ("Hulst")

Declaration of Sylvia D. Hall-Ellis, Ph.D.

Thomas et al., Effect of PCV2 passive antibody levels on immunization with chimeric PCV1-2 vaccine and challenge with wild-type PCV2, American Association of Swine Veterinarians, 23-26 (2005) ("Thomas")

Development and Formulation of Veterinary Dosage Forms, 2d Ed. (eds. D. Hardee & D. Baggot), CRC Press (1998) ("Hardee")

J. Segales, et al., Quantification of Porcine Circovirus Type 2 (PCV2) DNA, etc., 111 Veterinary Microbiology 223-229 (2005).

P. Offit & R. Jew, Addressing Parents' Concerns: Do Vaccines Contain Harmful Preservatives, Adjuvants, Additives, or Residuals?, 112 Pediatrics 6 (December 2003) ("Offit")

M. Mombarg, Is One More Than Two?, 34 IPVS Health Pig International 3 (March 2004) ("Mombarg")

R. Moorman, A. Bouma, J. Kramps, C. Terpstra, H. De Smit, Development of a Classical Swine Fever Subunit Marker Vaccine and Companion Diagnostic Test ("Moorman")

SIV Vaccine, dvm360 (Mar. 1, 2004), http://veterinarynews.dvm360.com/siv-vaccine.

Application No. 10174465.4 Information regarding oral proceedings of 12.09.18

D. Nilubol, et al,, The Effect of a Killed Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Vaccine Treatment on Virus Shedding in Previously PRRSV Infected Pigs, 102 Veterinary Microbiology 11-18 (2004) ("Nilubol")

W.L. Mengeling, T.T. Brown, P.S. Paul & D.E. Gutekunst, Efficacy of an Inactive Virus Vaccine for Prevention of Porcine Parvovirus-Induced Reproductive Failure, 40 Am. J. Vet. Res. 2 (Feb. 1979) ("Mengeling")

J. Srinivasappa, I. Morozou, M. Gill & H. Chu, Efficacy, Safety and Serological Cross-Reactivity of Fort Dodge Animal Health's Swine Influenza Vaccine, American Association of Swine Veterinarians (2003) ("Srinivasappa")

F. Brown, Inactivation of Viruses by Aziridines, 20 Vaccine 322-327 (2002) ("Brown")

P.A. Harms, et al., Experimental Reproduction of Severe Disease in CD/CD Pigs Concurrently Infected with Type 2 Porcine Circovirus and Porcine Reproductive and Respiratory Syndrome Virus, 38 Vet. Pathol. 528-539 (2001) ("Harms")

C. Charreyre, S. Beseme, L. Boeuf-Teseschi, M. Bublot & G. Reynaud, Protection Against PCV2 Experimental Challenge in 3 Week-Old Piglets by Maternal Antibodies, Proceedings of the 17th IPVS Congress, Ames, Iowa, USA (2002) ("Charreyre")

K. Diehl, et al., A Good Practice Guide to the Administration of Substances and Removal of Blood, Including Routes and Volumes, 21 J. Appl. Toxicol. 15-23 (2001) ("Deihl")

M. Fenaux, et al., Cloned Genomic DNA of Type 2 Porcine Circovirus is Infection, etc., 76 J. Virology, 2:541-551 (2002).

A. Olvera, et al., Comparison of Porcine Circovirus Type 2 Load in Serum Quantified by a Real Time PCR, etc., 117 J. Virological Methods 75-80 (2004).

E. Albina, et al., An Experimental Model for Post-weaning Multisystemic Wasting Syndrome (PMWS) in Growing Piglets, 125 J. Comp. Path. 292-303 (2001).

U.S. Patent No. 4,442,035

U.S. Patent No. 4,753,884

U.S. Patent No. 5,789,388

U.S. Patent No. 5,213,795

U.S. Patent No. 9,011,872

Declaration of Darin Madson, D.V.M., Ph.D.

Petition for Inter Partes Review of U.S. Patent No. 9,669,087